Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer

Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer

Abstract PIM and PI3K/mTOR pathways are often dysregulated in prostate cancer, and may lead to decreased survival, increased metastasis and invasion. The pathways are heavily interconnected and act on a variety of common effectors that can lead to the development of resistance to drug inhibitors. Mo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sabina Luszczak, Benjamin S. Simpson, Urszula Stopka-Farooqui, Vignesh Krishna Sathyadevan, Lina M. Carmona Echeverria, Christopher Kumar, Helena Costa, Aiman Haider, Alex Freeman, Charles Jameson, Marzena Ratynska, Imen Ben-Salha, Ashwin Sridhar, Greg Shaw, John D. Kelly, Hayley Pye, Kathy A. Gately, Hayley C. Whitaker, Susan Heavey
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/5720892a10484524bbddcc6413152966
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/5720892a10484524bbddcc6413152966

Ejemplares similares